Seres Therapeutics, Inc. (MCRB)
1.43
+0.02
(+1.42%)
USD |
NASDAQ |
Nov 18, 16:00
1.43
0.00 (0.00%)
After-Hours: 20:00
Seres Therapeutics Profit Margin (Quarterly) : -2.75K% for Sept. 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -2.75K% |
| June 30, 2026 | |
| March 31, 2026 | -5.56K% |
| December 31, 2025 | -3.50K% |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | 36.81% |
| March 31, 2023 | |
| December 31, 2022 | -7.06K% |
| September 30, 2022 | -1.74K% |
| June 30, 2022 | -5.32K% |
| March 31, 2022 | -3.79K% |
| December 31, 2021 | -692.4% |
| September 30, 2021 | 53.83% |
| June 30, 2021 | -918.3% |
| Date | Value |
|---|---|
| March 31, 2021 | -620.2% |
| December 31, 2020 | -103.9% |
| September 30, 2020 | -2.14K% |
| June 30, 2020 | -342.7% |
| March 31, 2020 | -242.8% |
| December 31, 2019 | -246.4% |
| September 30, 2019 | -233.4% |
| June 30, 2019 | -85.86% |
| March 31, 2019 | -332.4% |
| December 31, 2018 | -200.3% |
| September 30, 2018 | -242.4% |
| June 30, 2018 | -602.5% |
| March 31, 2018 | -703.1% |
| December 31, 2017 | -947.4% |
| September 30, 2017 | -30.13% |
| June 30, 2017 | -929.6% |
| March 31, 2017 | -844.9% |
| December 31, 2016 | -832.5% |
| September 30, 2016 | -143.6% |
| June 30, 2016 | -929.2% |
| March 31, 2016 | -727.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 4.98% |
| Amgen, Inc. | 37.29% |
| Anika Therapeutics, Inc. | -1.02% |
| BioCryst Pharmaceuticals, Inc. | 21.03% |
| Imunon, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -137.8% |
| Return on Assets | -41.42% |
| Return on Invested Capital | -45.90% |
| Gross Profit Margin (Quarterly) | 18.89% |
| Operating Margin (Quarterly) | -1.76K% |
| Return on Net Operating Assets | -63.87% |